BR112013014115A2 - polynucleotide delivery conjugates in vivo showing sensitive enzyme linkages - Google Patents
polynucleotide delivery conjugates in vivo showing sensitive enzyme linkagesInfo
- Publication number
- BR112013014115A2 BR112013014115A2 BR112013014115A BR112013014115A BR112013014115A2 BR 112013014115 A2 BR112013014115 A2 BR 112013014115A2 BR 112013014115 A BR112013014115 A BR 112013014115A BR 112013014115 A BR112013014115 A BR 112013014115A BR 112013014115 A2 BR112013014115 A2 BR 112013014115A2
- Authority
- BR
- Brazil
- Prior art keywords
- polynucleotide delivery
- sensitive enzyme
- delivery conjugates
- vivo showing
- linkages
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/05—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/96—Esters of carbonic or haloformic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/91—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/95—Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/10—Vectors comprising a non-peptidic targeting moiety
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061427936P | 2010-12-29 | 2010-12-29 | |
US13/336,028 US8426554B2 (en) | 2010-12-29 | 2011-12-23 | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages |
PCT/US2011/067588 WO2012092373A2 (en) | 2010-12-29 | 2011-12-28 | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013014115A2 true BR112013014115A2 (en) | 2019-09-24 |
Family
ID=46383848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013014115A BR112013014115A2 (en) | 2010-12-29 | 2011-12-28 | polynucleotide delivery conjugates in vivo showing sensitive enzyme linkages |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP2658579A4 (en) |
JP (1) | JP5941926B2 (en) |
KR (1) | KR20130136494A (en) |
CN (1) | CN103491982B (en) |
AU (1) | AU2011352204B2 (en) |
BR (1) | BR112013014115A2 (en) |
CA (1) | CA2816041C (en) |
CL (2) | CL2013001876A1 (en) |
MX (2) | MX341118B (en) |
NZ (1) | NZ611656A (en) |
PE (1) | PE20140198A1 (en) |
RU (1) | RU2619453C2 (en) |
SG (1) | SG189942A1 (en) |
WO (1) | WO2012092373A2 (en) |
ZA (1) | ZA201302896B (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2920304B1 (en) | 2012-11-15 | 2019-03-06 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
CA2919088A1 (en) * | 2013-08-07 | 2015-02-12 | Arrowhead Research Corporation | Polyconjugates for delivery of rnai triggers to tumor cells in vivo |
JOP20210043A1 (en) | 2015-10-01 | 2017-06-16 | Arrowhead Pharmaceuticals Inc | Compositions and Methods for Inhibiting Gene Expression of LPA |
MA45328A (en) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF |
CN110944985B (en) * | 2017-05-24 | 2022-12-13 | 特拉维夫大学拉玛特有限公司 | Chemiluminescent probe for imaging/detection of proteases |
WO2019113393A1 (en) | 2017-12-06 | 2019-06-13 | Avidity Biosciences Llc | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
WO2020139788A2 (en) * | 2018-12-28 | 2020-07-02 | Sirnaomics, Inc. | Targeted delivery of therapeutic molecules |
AU2021237465A1 (en) | 2020-03-19 | 2022-10-13 | Avidity Biosciences, Inc. | Compositions and methods of treating Facioscapulohumeral muscular dystrophy |
JP2024504475A (en) * | 2021-01-28 | 2024-01-31 | 南京▲樺▼冠生物技▲術▼有限公司 | Complexes and their use |
CN117480175A (en) * | 2021-06-24 | 2024-01-30 | 东北泰克诺亚奇股份有限公司 | Fluorescent probe |
KR20230016999A (en) * | 2021-07-27 | 2023-02-03 | 안동대학교 산학협력단 | Pharmaceutical composition comprising the extract from vespa velutina nigrithorax as an effective component for prevention or treatment of thrombosis and health functional food comprising the same |
CN113621003B (en) * | 2021-09-10 | 2023-02-03 | 国科温州研究院(温州生物材料与工程研究所) | Method for preparing organic molecule covalent modification functionalized nucleic acid material and application thereof |
AU2022345098A1 (en) | 2021-09-16 | 2024-04-04 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US6180095B1 (en) * | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
CA2395636A1 (en) * | 1999-12-30 | 2001-07-12 | Novartis Ag | Novel colloid synthetic vectors for gene therapy |
EP1257296A2 (en) * | 2000-02-24 | 2002-11-20 | Genentech, Inc. | Caspase activated prodrugs therapy |
EP1243276A1 (en) * | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
US7091186B2 (en) * | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
US7541330B2 (en) * | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
WO2007059404A2 (en) * | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
RU2430740C2 (en) * | 2006-08-18 | 2011-10-10 | Ф.Хоффманн-Ля Рош Аг | Polyconjugates for polynucleotide introduction in vivo |
CA2660842C (en) * | 2006-08-18 | 2012-03-13 | F. Hoffmann-La Roche Ag | Polyconjugates for in vivo delivery of polynucleotides |
CA2675014C (en) * | 2007-01-17 | 2016-03-29 | Immunomedics, Inc. | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites |
TW201004647A (en) * | 2008-05-20 | 2010-02-01 | Sigma Tau Ind Farmaceuti | Novel dual targeting antitumoural conjugates |
US8501930B2 (en) * | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
-
2011
- 2011-12-28 MX MX2013007316A patent/MX341118B/en active IP Right Grant
- 2011-12-28 SG SG2013029830A patent/SG189942A1/en unknown
- 2011-12-28 CN CN201180061179.6A patent/CN103491982B/en active Active
- 2011-12-28 AU AU2011352204A patent/AU2011352204B2/en active Active
- 2011-12-28 CA CA2816041A patent/CA2816041C/en active Active
- 2011-12-28 BR BR112013014115A patent/BR112013014115A2/en not_active IP Right Cessation
- 2011-12-28 PE PE2013001496A patent/PE20140198A1/en not_active Application Discontinuation
- 2011-12-28 JP JP2013547648A patent/JP5941926B2/en active Active
- 2011-12-28 WO PCT/US2011/067588 patent/WO2012092373A2/en active Application Filing
- 2011-12-28 NZ NZ611656A patent/NZ611656A/en not_active IP Right Cessation
- 2011-12-28 MX MX2016006733A patent/MX347298B/en unknown
- 2011-12-28 EP EP11853858.6A patent/EP2658579A4/en not_active Withdrawn
- 2011-12-28 KR KR1020137017195A patent/KR20130136494A/en not_active Application Discontinuation
- 2011-12-28 RU RU2013117286A patent/RU2619453C2/en active
-
2013
- 2013-04-22 ZA ZA2013/02896A patent/ZA201302896B/en unknown
- 2013-06-25 CL CL2013001876A patent/CL2013001876A1/en unknown
-
2015
- 2015-12-10 CL CL2015003580A patent/CL2015003580A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201302896B (en) | 2014-07-25 |
WO2012092373A3 (en) | 2013-10-24 |
WO2012092373A2 (en) | 2012-07-05 |
EP2658579A4 (en) | 2015-07-22 |
RU2013117286A (en) | 2015-03-10 |
JP2014505685A (en) | 2014-03-06 |
CL2015003580A1 (en) | 2016-07-15 |
NZ611656A (en) | 2014-10-31 |
CN103491982A (en) | 2014-01-01 |
AU2011352204B2 (en) | 2015-05-21 |
EP2658579A2 (en) | 2013-11-06 |
AU2011352204A1 (en) | 2013-05-02 |
RU2619453C2 (en) | 2017-05-16 |
JP5941926B2 (en) | 2016-06-29 |
CL2013001876A1 (en) | 2014-04-11 |
SG189942A1 (en) | 2013-06-28 |
MX2013007316A (en) | 2013-07-29 |
MX341118B (en) | 2016-08-09 |
MX347298B (en) | 2017-04-21 |
CN103491982B (en) | 2017-09-12 |
PE20140198A1 (en) | 2014-02-21 |
KR20130136494A (en) | 2013-12-12 |
CA2816041A1 (en) | 2012-07-05 |
CA2816041C (en) | 2019-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013014115A2 (en) | polynucleotide delivery conjugates in vivo showing sensitive enzyme linkages | |
DK2437790T3 (en) | conjugation | |
BRPI0917000A2 (en) | protein conjugates with prolonged in vivo efficacy | |
IL216325A0 (en) | Polyal drug conjugates comprising variable rate-releasing linkers | |
DK2475294T3 (en) | Implantable sensor | |
IL252115B (en) | Lysosomal storage disease enzyme | |
BRPI1010279A2 (en) | drug delivery device | |
IL218523A0 (en) | Extracellular targeted drug conjugates | |
BRPI1012730A2 (en) | drug delivery device | |
BRPI0920514A2 (en) | drug infusion | |
BRPI1012902A2 (en) | development sensor sets | |
BR112012001260A2 (en) | epsilon-polylysine conjugates and their use | |
BRPI1010237A2 (en) | drug delivery device | |
BRPI1016117A2 (en) | isoxazole-isoxazole and isoxasol-isothiazole derivatives. | |
BR112012000799A2 (en) | drug delivery device | |
DK2437736T3 (en) | drug delivery | |
BRPI1016016A2 (en) | shaft bearing and needle bearing. | |
GB201107182D0 (en) | Improvements in or relating to sensing arrangements | |
IT1394046B1 (en) | SARCHARIZER WITH ROTATING ORGANS IN GANCIFORMS ELEMENTS | |
DK2501251T3 (en) | Functional insole | |
DK2396056T3 (en) | insulin Delivery | |
BRPI1014705A2 (en) | dosing device with articulation device | |
IT1398857B1 (en) | FOSPHOLIPID POLYMERIC CONJUGATES | |
DK2509593T3 (en) | PROTEIN POLYMER CONJUGATES | |
BR112013001508A2 (en) | pharmaceutical composition with enhanced solubility characteristics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |